K. Uemura

This study identifies 2-thiouridine as a broad-spectrum antiviral against SARS-CoV-2 and other positive-strand RNA viruses by inhibiting viral RNA synthesis.

This study shows that oral S-217622 reduces SARS-CoV-2 viral load and improves recovery in hamsters, with activity against multiple variants.

This paper describes the discovery of S-217622, an oral non-covalent SARS-CoV-2 3CL protease inhibitor showing antiviral activity and favorable pharmacokinetics in preclinical studies.

This study shows that SARS-CoV-2 variants with mutations at the furin cleavage site are less virulent and induce protective immunity in hamsters.

This study shows that SARS-CoV-2 variants with mutations at the S1/S2 cleavage site emerge in TMPRSS2-deficient cells, leading to reduced cell tropism and plaque size.